Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07710430
PHASE4

A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty

Sponsor: LG Chem

View on ClinicalTrials.gov

Summary

A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty

Official title: A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children With Central Precocious Puberty

Key Details

Gender

All

Age Range

Any - 10 Years

Study Type

INTERVENTIONAL

Enrollment

43

Start Date

2026-08-01

Completion Date

2030-04-30

Last Updated

2026-07-17

Healthy Volunteers

No

Interventions

DRUG

Leuprorelin

Leuprorelin will be administered every 4 weeks.